Calciphilaxis in chronic renal failure : 3 cases

##plugins.themes.academic_pro.article.main##

Hayet Kaaroud
Soumaya Béji
Ines Souissi
Fethi Ben Hamida
Karim Zouaghi
Fatma Ben Moussa
Fethi El Younsi
Ezzedine Abderrahim
Taieb Ben Abdallah
Hedi Ben Maiz
Adel Khedher

Abstract

Background: Calciphylaxis is a small vessel disease responsible for vascular calcification and skin necrosis. It occurs in association with chronic renal failure and has a poor prognosis.
But : Report new cases. We report 3 cases of calciphylaxis occurred in patients with chronic renal failure secondary to interstitial nephritis in 1 case, diabetic nephropathy in 1 case and thrombotic microangiopathy in 1 case.
Cases: They were 2 females an 1 man aged of 44,3 years meanly. Hyperphosphoremia and hyperparathyroidism were the essential risk factors. All patients died by sepsis. This course was precipitating by corticotherapy in 2 cases.
Conclusion: Early recognition and treatment of risk factors is mandatory to reduce mortality in uremic patients with calciphylaxis

Keywords:

Calciphylaxis, Chronic renal failure, Haemodialysis, Mortality

##plugins.themes.academic_pro.article.details##

References

  1. Dennis H , Eulau D, Tokugawa DA, Mc Guire JS, Kohler S. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol 1999,40:979-87.
  2. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery 1997,122:1083-90.
  3. McAuley K, Devereux F, Walker R. Calciphylaxis in tow noncompliant patients with end-stage renal failure. Nephrol Dial Transplant 1997; 12: 1061-1063.
  4. Roe SM, Graham LD, Brock WB, Barker DE . Calciphylaxis: Early recognition and management. Am Surg.1994; 2; 81-86.
  5. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H. Dexamethasone enhances In vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:2112-2118.
  6. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978-982.
  7. Younis N, Sells RA, Desmond A, Helliwell T, Guerin D, Jibani M et al. Painful cutaneous lesions, renal failure and urgent parathyroidectomy. J Nephrol 2002; 15: 324-329.
  8. Davies MR, Hruska KA . Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001; 60: 472-9
  9. Fournier A. CaCO3 dose and risk of arterial calcification.. Nephrol DialTransplant 2001 16:1075.
  10. Perez-Mijares R, Guzman-Zamudio JL, Payan-Lopez J, Rodriguez-Fernandez P, Gomez-Fernandez P, Almaraz-Jimenez M. Calciphylaxis in a haemodialysis patient: Functional protein S deficiency?. Nephrol Dial Transplant 1996 11:1856-1859.
  11. Asmundsson P, Eliasson GJ, Pordarson H. A case of calciphylaxis. Scand J Urol Nephrol 1988;22:155-157,
  12. Cicone JS., Petronis JB., Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis, 2004 ; 6: 1104-8.
  13. Hayden MR, Tyagi SC, Kolb L et al. Vascular ossification calcificationin metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4: 4.
  14. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriopathy: a case series. J Nephrol 2002; 15(6):676-80
  15. Milas M., Bush RL., Lin P, Brown K., Mackay G., Lumsden A et al. Calciphylaxis and nonhealing wounds: the role of the vascular surgeon in a multidisciplinary treatment. J vasc surg 2003;37(3): 501-7.
  16. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; (60): 324-32.
  17. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG. Therapy for calciphylaxis: An outcome analysis. Surgery 2003;134:941-5.